Melody A Cobleigh
Overview
Explore the profile of Melody A Cobleigh including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
2456
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
OConnell B, Hubbard C, Zizlsperger N, Fitzgerald D, Kutok J, Varner J, et al.
J Immunother Cancer
. 2024 Aug;
12(8).
PMID: 39214650
Background: Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer with a poor prognosis particularly in the metastatic setting. Treatments with anti-programmed cell death protein-1/programmed death-ligand 1 (PD-L1)...
2.
Cobleigh M, Layng K, Mauer E, Mahon B, Hockenberry A, Abukhdeir A
Breast Cancer Res Treat
. 2023 Dec;
204(2):407-414.
PMID: 38153569
Purpose: The PIK3R1 gene encodes the regulatory subunit-p85a-of the PI3K signaling complex. Prior studies have found that pathogenic somatic alterations in PIK3R1 are enriched in human breast cancers but the...
3.
Vogel C, Cobleigh M, Tripathy D, Gutheil J, Harris L, Fehrenbacher L, et al.
J Clin Oncol
. 2023 Mar;
41(9):1638-1645.
PMID: 36921335
Purpose: To evaluate the efficacy and safety of first-line, single-agent trastuzumab in women with -overexpressing metastatic breast cancer. Patients And Methods: One hundred fourteen women with -overexpressing metastatic breast cancer...
4.
Cobleigh M, Vogel C, Tripathy D, Robert N, Scholl S, Fehrenbacher L, et al.
J Clin Oncol
. 2023 Mar;
41(8):1501-1510.
PMID: 36881998
Purpose: Overexpression of the HER2 protein occurs in 25% to 30% of human breast cancers and leads to a particularly aggressive form of the disease. Efficacy and safety of recombinant...
5.
Cobleigh M, Anderson S
J Clin Oncol
. 2021 Sep;
39(30):3410-3411.
PMID: 34473528
No abstract available.
6.
Cobleigh M, Anderson S, Siziopikou K, Arthur D, Rabinovitch R, Julian T, et al.
J Clin Oncol
. 2021 Mar;
39(21):2367-2374.
PMID: 33739848
Purpose: Preclinical studies report that trastuzumab (T) can boost radiotherapy (RT) effectiveness. The primary aim of the B-43 trial was to assess the efficacy of RT alone vs concurrent RT...
7.
DiScala M, Najor M, Yung T, Morgan D, Abukhdeir A, Cobleigh M
PLoS One
. 2020 Jun;
15(6):e0234146.
PMID: 32525891
Approximately 20% of breast cancers are HER2-positive. Trastuzumab has improved patient outcomes significantly for these cancers. However, acquired resistance remains a major hurdle in the clinical management of these patients....
8.
Chowdhary M, Sen N, Chowdhary A, Usha L, Cobleigh M, Wang D, et al.
Adv Radiat Oncol
. 2019 Jul;
4(3):453-457.
PMID: 31360799
Purpose: Palbociclib is a selective cyclin-dependent kinase 4/6 inhibitor approved for metastatic ER+/HER2- breast cancer. Preclinical evidence suggests a possible synergistic effect of palbociclib when combined with radiation therapy (RT);...
9.
Turturro S, Najor M, Yung T, Portt L, Malarkey C, Abukhdeir A, et al.
Breast Cancer Res Treat
. 2019 Jun;
177(2):325-333.
PMID: 31209687
Purpose: The PI3K pathway, which includes the PI3K catalytic subunits p110α (PIK3CA) and the PI3K regulatory subunit p85α (PIK3R1), is the most frequently altered pathway in cancer. We encountered a...
10.
Njoroge S, Burgess K, Cobleigh M, Alnajar H, Gattuso P, Usha L
Breast Cancer Res Treat
. 2017 Jul;
166(1):315-319.
PMID: 28702897
Introduction: Genetic counseling and testing is recommended for women with a personal and/or family history of breast and other cancers (ovarian, pancreatic, male breast and others). Mutations in the BRCA1...